上海交通大学学报（医学版）

上海交通大学学报（医学版）

• 论著（临床研究） • 上一篇    下一篇

康柏西普对糖尿病性黄斑水肿的疗效评价

孙清磊 1，闫焱 1，祝丽娜 1，秦晓玲 2，谭烨 3，刘洁 4，谭海波 1，宁利 1，柳林 1   

  1. 1.上海交通大学 医学院附属仁济医院眼科，上海 200127；2.上海市浦东新区陆家嘴社区卫生服务中心眼科，上海 200120；3.上海市浦东新区公利医院眼科，上海 200135；4.上海市浦东新区潍坊社区卫生中心眼科，上海 200122
  • 出版日期:2017-05-28 发布日期:2017-05-31
  • 通讯作者: 柳林，电子信箱：18918358758@163.com。
  • 作者简介:孙清磊（1990—），男，住院医师，硕士生；电子信箱：conansun1990@163.com。
  • 基金资助:

    上海市浦东新区卫生局卫生（计生）科技项目（PW2013D-1）；上海市卫生和计划生育委员会面上项目（M20140513）

Clinical efficacy of intravitreal injection of Conbercept in treatment of diabetic macular edema

SUN Qing-lei1, YAN Yan1, ZHU Li-na1, QIN Xiao-ling2, TAN Ye3, LIU Jie4, TAN Hai-bo1, NING Li1, LIU Lin1   

  1. 1. Department of Ophthalmology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; 2. Department of Ophthalmology, Lujiazui Community Health Service Center, Shanghai 200120, China; 3. Department of Ophthalmology, Gongli Hospital, Shanghai 200135, China; 4. Department of Ophthalmology, Weifang Community Health Center, Shanghai 200122, China

  • Online:2017-05-28 Published:2017-05-31
  • Supported by:

    Science and Technology Project of Health Bureau of Pudong New Area, Shanghai, PW2013D-1; Project of Shanghai Municipal Commission of Health and Family Planning General, M20140513

PDF (PC)

1219

摘要：

目的 ·评价玻璃体腔内注射抗血管内皮生长因子（VEGF）药物康柏西普对治疗糖尿病性黄斑水肿（DME）的临床效果。方法 ·选取DME（炎症型）患者11例17眼, 每月行1次康柏西普玻璃体腔内注射，首次治疗之后按需治疗。治疗结束后随诊6个月以上，比较治疗前后患者的最佳矫正视力（BCVA）、中央视网膜厚度（CRT）、DME消退率及眼底荧光血管造影检查（FFA）结果。结果 ·随访时间为7～29个月，平均（12±7）个月。注射针数1～10针，平均针数为（4±3）针。 DME患者注药后BCVA明显提高（t=7.306，P=0.001），CRT下降显著（t=5.272，P=0.000），差异有统计学意义。DME总消退率为76.5%。结论 ·玻璃体腔内注射抗VEGF药物康柏西普，可明显改善DME患者的视力，明显消退黄斑水肿症状。

关键词: 糖尿病性黄斑水肿, 康柏西普, 最佳矫正视力, 中央视网膜厚度

Abstract:

Objective · To investigate the clinical effect of intravitreal injection of Conbercept in the treatment of diabetic macular edema (DME). Methods · Eleven patients (17 eyes) with DME (inflammatory type) received intravitreal injection of Conbercept monthly. After the first treatment, the patients were treated on demand. Follow-up after treatment for more than 6 months, the best corrected visual acuity (BCVA), central retinal thickness (CRT), diminished rate of DME and result of fundus fluorescein angiography(FFA) of DME eyes before and after treatment were compared. Results · During a follow-up of 7-29 months [(12±7) months], the injections were given 1-10 times [(4±3) times]. The results showed that the treatment effects on improving BCVA (logMAR) and diminishing of CRT were significant (t=7.306, P=0.001; t=5.272, P=0.000). The diminished rate of DME of our patients was 76.5%. Conclusion · Intravitreal injection of Conbercept in the treatment of DME is effective on reducing macular edema and improving visual acuity.

Key words: diabetic macular edema, Conbercept, the best corrected visual acuity, central retinal thickness